Type-2 Diabetes
Conditions
Keywords
diabetes, cardiovascular risk
Brief summary
Incretin-based therapies have shown significant effects beyond those on glucose metabolism. We aim in the present study to evaluate the effects of liraglutide on several cardio-metabolic risk markers.
Detailed description
In details, we will evaluate the effects of liraglutide on carotid-intima media thickness, oxidative stress, ghrelin, heat shock proteins and lipoproteins.
Interventions
None listed
Sponsors
University of Palermo
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
\- patients with a diagnosis of type-2 diabetes
Exclusion criteria
\- severe hepatic or renal diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| carotid intima-media thickness | every four months for a total period of 2 years | carotid intima-media thickness will be assessed by doppler ultrasonography |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| changes in oxidative stress markers | after 2 months of therapy | Serum LOOH levels were evaluated following the oxidation of Fe2+ to Fe3+ in the presence of xylenol orange at 560 nm. Levels of GSH were measured in serum using a spectrophotometric assay based on the reaction of thiol groups with 2,2-dithio-bis-nitrobenzoic acid, while the production of ROS was assessed using fluorescent probe dihydroethidium staining (Sigma). |
| changes in plasma ghrelin concentrations and heat-shock proteins | after 2 months of therapy | plasma ghrelin concentrations and heat shock protein 60 were measured by ELISA |
| changes in atherogenic lipoproteins | after 2 and after 4 months of therapy | the full LDL subclass profile (from larger and less atherogenic LDL-1 and LDL-2, to smaller denser LDL-3 to LDL-7) was assessed by gel electrophoresis (Lipoprint, Quantimetrix, USA) |
Countries
Italy
Outcome results
None listed